Resuscitec GmbH Revenue and Competitors
Estimated Revenue & Valuation
- Resuscitec GmbH's estimated annual revenue is currently $14.8M per year.
- Resuscitec GmbH's estimated revenue per employee is $251,000
Employee Data
- Resuscitec GmbH has 59 Employees.
- Resuscitec GmbH grew their employee count by 0% last year.
Resuscitec GmbH's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head CARL Support Clincal & Technical & CARL Academy | Reveal Email/Phone |
2 | Head Quality Management and Regulatory Affairs | Reveal Email/Phone |
3 | Leiter der Arbeitsvorbereitung / Produktionsplanung | Reveal Email/Phone |
4 | Prozesstechniker Produktion | Reveal Email/Phone |
5 | Master-Student | Reveal Email/Phone |
6 | Testingenieur Entwicklung | Reveal Email/Phone |
7 | Operativer Einkäufer | Reveal Email/Phone |
8 | Forschungs- und Entwicklungsingenieur | Reveal Email/Phone |
9 | Teamleiter Prozessentwicklung und Validierung | Reveal Email/Phone |
10 | Embedded Software Ingenieur | Reveal Email/Phone |
Resuscitec GmbH Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $15.8M | 63 | -19% | N/A | N/A |
#2 | $96.1M | 383 | -32% | N/A | N/A |
#3 | $3M | 12 | -65% | N/A | N/A |
#4 | $80.3M | 320 | 25% | N/A | N/A |
#5 | $14.1M | 56 | -7% | N/A | N/A |
#6 | $89.6M | 357 | 28% | N/A | N/A |
#7 | $26.9M | 107 | -5% | N/A | N/A |
#8 | $27.4M | 109 | 35% | N/A | N/A |
#9 | $117.5M | 468 | N/A | N/A | N/A |
#10 | $25.4M | 101 | 5% | N/A | N/A |
What Is Resuscitec GmbH?
Resuscitec GmbH – Life is our Mission Resuscitec GmbH is a medical device company based in Freiburg, Germany. Our company was founded in 2010 as a spin-off of the University Hospital Freiburg and focusses on the development and commercialization of systems and products designed for emergencies. We produce and distribute the CARL System, the world's first mobile resuscitation system that can be used to implement the CARL Therapy. The CARL Therapy aims to prevent severe neurological sequelae during resuscitation of patients suffering an acute cardiac arrest in or out of hospital. This can be achieved, even after a prolonged cardiac arrest, by the provision of a controlled, targeted and personalized extracorporeal circulation.
keywords:N/A
N/A
Total Funding
59
Number of Employees
$14.8M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Freiburg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.7M | 59 | 26% | N/A |
#2 | $9.1M | 72 | -11% | N/A |
#3 | $13.3M | 73 | 22% | N/A |
#4 | $14.6M | 77 | 166% | N/A |
#5 | $16.8M | 83 | 22% | N/A |